Clinical Trial

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity

Study acronym: MASAMUNE
Recruiting
View on ClinicalTrials.gov →
Summary
Single-arm, prospective registry study assessing changes in acute patient-reported urinary (GU) and gastrointestinal (GI) quality of life at the 24-month post-treatment time point following magnetic resonance imaging (MRI)-guided or computed tomography (CT)-guided stereotactic body radiotherapy (SBRT) delivered to the prostate bed +/- pelvic lymph nodes. The decision to offer an adaptive treatment will be at the clinician's discretion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-11.
Status change: Not Yet Recruiting → Recruiting 2025-07-21
Trial Details
NCT Number NCT07077239
Lead Sponsor Jonsson Comprehensive Cancer Center
Conditions Prostate Cancer (CRPC)
Enrollment 200 participants
Start Date 2025-07-17
Primary Completion 2035-08-01 (estimated)
Study Completion 2036-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-24